Brandon Griffin joins Advantar Labs

Appointed as vp of sales and marketing

Advantar Labs, a contract provider of GLP and GMP research, formulation development and small-scale clinical packaging services, has added Brandon Griffin to its senior management team as vp of sales and marketing.

The San Diego, California, US-based company has an aggressive expansion plan following triple-digit growth in 2010.

Griffin will head the planning, implementation and management of Advantar’s sales and marketing strategy.

He was previously western regional vp of sales at RohnerChem, a Switzerland-based CMO, heading sales for large-scale custom synthesis of small molecules and novel monomers/biopolymers in the US.

You may also like

Research & Development

From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater

A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Packaging

Coding and marking innovation takes centre stage at Interpack 2026

Linx Printing Technologies and Domino Printing Sciences are unveiling systems that promise to address longstanding production challenges, including those specific to pharmaceutical and life sciences manufacturing.
Drug Delivery

Neuland Laboratories to partner with LIR Life Sciences for transdermal GLP-1 development

The pair will work to advance LIR Life's novel cell-penetrating peptides for next-generation obesity therapies, looking to improve patient adherence and broaden access
Manufacturing

BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany

The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Finance

Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings

The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
Subscribe now